Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Artigo em Inglês | MEDLINE | ID: mdl-38705259

RESUMO

BACKGROUND: The integrity of the airway epithelium is guarded by the airway basal cells that serve as progenitor cells and restore wounds in case of injury. Basal cells are a heterogenous population, and specific changes in their behavior are associated with chronic barrier disruption-mechanisms that have not been studied in detail in allergic rhinitis (AR). OBJECTIVE: We aimed to study basal cell subtypes in AR and healthy controls. METHODS: Single-cell RNA sequencing (scRNA-Seq) of the nasal epithelium was performed on nonallergic and house dust mite-allergic AR patients to reveal basal cell diversity and to identify allergy-related alterations. Flow cytometry, immunofluorescence staining, and in vitro experiments using primary basal cells were performed to confirm phenotypic findings at the protein level and functionally. RESULTS: The scRNA-Seq, flow cytometry, and immunofluorescence staining revealed that basal cells are abundantly and heterogeneously present in the nasal epithelium, suggesting specialized subtypes. The total basal cell fraction within the epithelium in AR is increased compared to controls. scRNA-Seq demonstrated that potentially beneficial basal cells are missing in AR epithelium, while an activated population of allergy-associated basal cells is more dominantly present. Furthermore, our in vitro proliferation, wound healing assay and air-liquid interface cultures show that AR-associated basal cells have altered progenitor capacity compared to nonallergic basal cells. CONCLUSIONS: The nasal basal cell population is abundant and diverse, and it shifts toward a diseased state in AR. The absence of potentially protective subtypes and the rise of a proinflammatory population suggest that basal cells are important players in maintaining epithelial barrier defects in AR.

2.
Artigo em Inglês | MEDLINE | ID: mdl-39151476

RESUMO

BACKGROUND: Responder analyses of SINUS phase 3 study data have shown clinically meaningful improvements across multiple chronic rhinosinusitis with nasal polyps (CRSwNP) outcomes with dupilumab. OBJECTIVE: To gain a better understanding of dupilumab response dynamics over 52 weeks. METHODS: Post hoc analysis using data from the SINUS-52 (NCT02898454) intention-to-treat population, of patients with severe CRSwNP who received dupilumab 300 mg once every 2 weeks (q2w) or placebo. Response, defined as an improvement from baseline of ≥ 1 point for Nasal Polyp Score (NPS), nasal congestion (NC), and loss of smell (LoS), and ≥ 8.9 points for 22-item Sino-Nasal Outcome Test (SNOT-22), was assessed for rapidity, maintenance, and durability. RESULTS: 303 patients (dupilumab, n = 150; placebo, n = 153) were included. For each outcome measure, a greater proportion of patients achieved first response by Week 16 (rapidity) with dupilumab vs placebo: NPS, 75.3% vs 39.2%; NC, 60.0% vs 24.2%; LoS, 60.7% vs 15.7%; and SNOT-22, 83.3% vs 66.0%. Among dupilumab patients with a response by Week 16, more than 80% maintained response at Week 52 (maintenance). Over 52 weeks, greater proportions of dupilumab patients were responders at ≥ 80% of time points: NPS, 46.7% vs 2.6%; NC, 46.7% vs 9.2%; LoS, 47.3% vs 3.9%; and SNOT-22, 62.0% vs 21.6% (durability). CONCLUSION: Most CRSwNP patients achieve clinically meaningful responses to dupilumab by Week 16, and most of these patients had maintenance and durability of response with continued treatment over time.

3.
Allergy ; 79(5): 1123-1133, 2024 05.
Artigo em Inglês | MEDLINE | ID: mdl-38108602

RESUMO

Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.


Assuntos
Pólipos Nasais , Rinossinusite , Humanos , Doença Crônica , Gerenciamento Clínico , Pólipos Nasais/terapia , Pólipos Nasais/diagnóstico , Rinossinusite/diagnóstico , Rinossinusite/terapia
4.
Pediatr Allergy Immunol ; 35(7): e14183, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38949196

RESUMO

The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual forum EUFOREUM in Berlin in November 2023. The aim of EUFOREUM 2023 was to highlight pediatric action plans for prevention and optimizing care for type 2 inflammatory conditions starting in childhood, with a focus on early-stage diagnosis, ensuring neither under- nor overdiagnosis, optimal care, and suggestions for improvement of care. EUFOREA is an international not-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in the keynote lectures and faculty of the virtual EUFOREUM 2023 (www.euforea.eu/euforeum) coming from the pediatric, allergology, pulmonology, ENT, dermatology, primary health care fields and patients around the central theme of type 2 inflammation. As most type 2 inflammatory conditions may start in childhood or adolescence, and most children have type 2 inflammation when suffering from a respiratory or skin disease, the moment has come to raise the bar of ambitions of care, including prevention, remission and disease modification at an early stage. The current report provides a comprehensive overview of key statements by the faculty of the EUFOREUM 2023 and the ambitions of EUFOREA allowing all stakeholders in the respiratory field to be updated and ready to join forces in Europe and beyond.


Assuntos
Inflamação , Adolescente , Criança , Humanos , Alergia e Imunologia , Berlim , Inflamação/diagnóstico , Pediatria , Congressos como Assunto
5.
Facial Plast Surg ; 40(3): 275-286, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38224694

RESUMO

Impairment of nasal breathing is a highly prevalent and bothersome symptom that affects daily functioning and/or sleep quality. Those surgeons dealing with patients seeking rhinoplasty need to carefully analyze the preoperative nasal breathing capacity and predict the positive or even negative impact of rhino(septo)plasty on nasal breathing. Given the lack of correlation between the subjective feeling of suboptimal nasal breathing and the objective measurements of nasal flow and nasal resistance, a critical and mainly clinical evaluation of all anatomical, mucosal, and sensory mechanisms involved in nasal obstruction is mandatory. Indeed, thermo-, mechano-, and chemosensory receptors on the nasal mucosa, airflow, and respiratory dynamics might all contribute to the overall perception of nasal breathing capacity. In this review, we provide an overview of the factors determining suboptimal nasal breathing including different diagnostic and experimental tests that can be performed to evaluate nasal flow and nasal resistance and current limitations in our understanding of the problem of nasal breathing in an individual patient. An algorithm for the preoperative or diagnostic workup for nasal obstruction is included that might be useful as a guide for clinicians dealing with patients seeking nose surgery.


Assuntos
Obstrução Nasal , Rinoplastia , Humanos , Obstrução Nasal/cirurgia , Obstrução Nasal/fisiopatologia , Rinoplastia/métodos , Septo Nasal/cirurgia , Cuidados Pré-Operatórios/métodos , Resistência das Vias Respiratórias/fisiologia , Respiração , Mucosa Nasal/fisiopatologia , Rinomanometria
6.
Front Immunol ; 15: 1394539, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39176088

RESUMO

There is growing evidence that neurogenic inflammation contributes to the pathophysiology of upper airway diseases, with nasal hyperreactivity (NHR) being a key symptom. The rare neuroendocrine cells (NECs) in the epithelium have been linked to the pathophysiology of bronchial and intestinal hyperreactivity, however their presence in the nasal mucosa and their potential role in NHR remains unclear. Therefore, we studied the presence of NECs in the nasal epithelium of controls, allergic rhinitis patients and chronic rhinosinusitis with nasal polyps patients, and their link to NHR. The expression of typical NECs markers, CHGA, ASCL1 and CGRP, were evaluated on gene and protein level in human samples using real-time quantitative PCR (RT-qPCR), western blot, immunohistochemistry fluorescence staining, RNA scope assay, flow cytometry and single cell RNA-sequencing. Furthermore, the change in peak nasal inspiratory flow after cold dry air provocation and visual analogue scale scores were used to evaluate NHR or disease severity, respectively. Limited gene expression of the NECs markers CHGA and ASCL1 was measured in patients with upper airway diseases and controls. Gene expression of these markers did not correlate with NHR severity nor disease severity. In vitro, CHGA and ASCL1 expression was also evaluated in primary nasal epithelial cell cultures from patients with upper airway disease and controls using RT-qPCR and western blot. Both on gene and protein level only limited CHGA and ASCL1 expression was found. Additionally, NECs were studied in nasal biopsies of patients with upper airway diseases and controls using immunohistochemistry fluorescence staining, RNA scope and flow cytometry. Unlike in ileum samples, CHGA could not be detected in nasal biopsies of patients with upper airway diseases and control subjects. Lastly, single cell RNA-sequencing of upper airway tissue could not identify a NEC cluster. In summary, in contrast to the bronchi and gut, there is only limited evidence for the presence of NECs in the nasal mucosa, and without correlation with NHR, thereby questioning the relevance of NECs in upper airway pathology.


Assuntos
Mucosa Nasal , Pólipos Nasais , Células Neuroendócrinas , Humanos , Mucosa Nasal/metabolismo , Mucosa Nasal/patologia , Mucosa Nasal/imunologia , Feminino , Adulto , Masculino , Células Neuroendócrinas/metabolismo , Células Neuroendócrinas/patologia , Pessoa de Meia-Idade , Pólipos Nasais/imunologia , Pólipos Nasais/patologia , Pólipos Nasais/metabolismo , Sinusite/metabolismo , Sinusite/patologia , Sinusite/imunologia , Rinite Alérgica/metabolismo , Rinite Alérgica/imunologia , Rinite Alérgica/patologia , Biomarcadores , Fatores de Transcrição Hélice-Alça-Hélice Básicos/genética , Fatores de Transcrição Hélice-Alça-Hélice Básicos/metabolismo , Células Cultivadas
7.
World Allergy Organ J ; 17(1): 100849, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-38225952

RESUMO

Background: House dust mite (HDM)-induced allergic rhinitis (AR) is a major cause of allergic respiratory disease. The efficacy and safety of the 300 IR HDM sublingual immunotherapy (SLIT) tablet in patients with moderate-to-severe HDM-AR was confirmed in a large, international, phase 3 randomized controlled trials (RCTs). Here, we analyzed the results in the European population. Methods: Data from 91 European centers that participated in the international, double-blind, RCT (EudraCT 2014-004223-46, NCT02443805) with the 300 IR HDM SLIT tablet versus placebo over 12 months were analyzed post hoc. The treatment effect in European adults and adolescents was notably assessed through the European Academy of Allergy and Clinical Immunology (EAACI)-recommended combined symptom and medication score (CSMS0-6, pre-defined endpoint) and the total combined rhinitis score (TCRS0-24, post hoc endpoint, also balanced) during the primary evaluation period (4 weeks at the end of treatment period) using analysis of covariance (ANCOVA). Results: There were 818 patients who comprised the modified full analysis set in Europe. Over the primary period, the differences in CSMS0-6 and TCRS0-24 between the 300 IR and placebo groups were statistically significant (p < 0.0001): -0.32 (95%CI [-0.46; -0.17]) and -1.28 (95%CI [-1.63; -0.94]), respectively, with relative differences of -20.9% and -21.2%. All post hoc and the rhinoconjunctivitis quality of life endpoints were significantly improved with 300 IR versus placebo. The 300 IR HDM tablet was generally well tolerated. Conclusion: This RCT sub-analysis confirmed the 300 IR HDM SLIT tablet is an effective and safe treatment for European adults and adolescents with HDM-AR with clinically meaningful benefits from the patients' perspective. Trial registration: NCT02443805. Registered on April 29, 2015./EudraCT 2014-004223-46. Registered on September 16, 2015.

9.
Bousque, Jean; Schunemann, Holger J; Togias, Akdis; Bachert, Claus; Erhola, Martina; Hellings, Peter W; Klimek, Ludger; Pfaar, Oliver; Wallace, Dana; Ansotegui, Ignacio; Agache, Ioana; Bedbrook, Anna; Bergmann, MKarl-Christian; Bewick, Mike; Bonniaud, Philippe; Bosnic-Anticevich, Sinthia; Bosse, Isabelle; Bouchard, Jacques; Boulet, Louis-Philippe; Brozek, Jan; Brusselle, Guy; Calderon, Moises A; Canonica, Walter G; Caraballo, Luis; Cardona, Vicky; Casale, Thomas; Cecchi, Lorenzo; Chu, Derek K; Costa, Elisio M; Cruz, Alvaro A; Czarlewski, Wienczyslawa; D'Amato, Gennaro; Devillier, Philippe; Dykewicz, Mark; Ebisawa, Motohiro; Fauquert, Jean-Louis; Fokkens, Wytske J; Fonseca, Joao A; Fontaine, Jean-Francois; Gemicioglu, Bilun; van Wijk, Roy Gerth; Haahtela, Tari; Halken, Susanne; Ierodiakonou, Despo; Iinuma, Tomohisa; Ivancevich, Juan-Carlos; Jutel, Marek; Kaidashev, Igor; Khaitov, Musa; Kalayci, Omer; Tebbe, Jorg Kleine; Kowalski, Marek L; Kuna, Piotr; Kvedariene, Violeta; La Grutta, Stefania; Larenas-Linnemann, Desiree; Lau, Susanne; Laune, Daniel; Le, Lan; Lieberman, Philipp; Lodrup Carlsen, Karin C; Lourenço, Olga; Marien, Gert; Carreiro-Martins, Pedro; Melen, Erik; Menditto, Enrica; Neffen, Hugo; Mercier, Gregoire; Mosgues, Ralph; Mullol, Joaquim; Muraro, Antonella; Namazova, Leyla; Novellino, Ettore; O'Hehir, Robyn; Okamoto, Yoshitaka; Ohta, Ken; Park, Hae Sim; Panzner, Petr; Passalacqua, Giovanni; Pham-Thi, Nhan; Price, David; Roberts, Graham; Roche, Nicolas; Rolland, Christine; Rosario, Nelson; Ryan, Dermot; Samolinski, Boleslaw; Sanchez-Borges, Mario; Scadding, Glenis K; Shamji, Mohamed H; Sheikh, Aziz; Bom, Ana-Maria Todo; Toppila-Salmi, Sanna; Tsiligianni, Ioana; Valentin-Rostan, Marylin; Valiulis, Arunas; Valovirta, Erkka; Ventura, Maria-Teresa; Walker, Samantha; Waserman, Susan; Yorgancioglu, Arzu; Zuberbier, Torsten.
J. allergy clin. immunol ; 145(1): [70-80], Jan. 2020.
Artigo em Inglês | BIGG | ID: biblio-1117204

RESUMO

The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm.


Assuntos
Humanos , Rinite Alérgica Sazonal/prevenção & controle , Resultado do Tratamento , Antialérgicos/uso terapêutico , Rinite Alérgica/prevenção & controle , Rinite Alérgica/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa